<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">Cell and Tissue Biology</journal-id><journal-title-group><journal-title xml:lang="en">Cell and Tissue Biology</journal-title><trans-title-group xml:lang="ru"><trans-title>Цитология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0041-3771</issn><issn publication-format="electronic">3034-6061</issn><publisher><publisher-name xml:lang="en">The Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">669498</article-id><article-id pub-id-type="doi">10.31857/S0041377124040025</article-id><article-id pub-id-type="edn">QDCKFT</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Melanoma cells adhesive properties activation in 3d spheroids</article-title><trans-title-group xml:lang="ru"><trans-title>Активация адгезивных свойств клеток меланомы в условиях 3d-культивирования</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Chernykh</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Черных</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>tatyana_ruksha@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zinchenko</surname><given-names>I. S.</given-names></name><name xml:lang="ru"><surname>Зинченко</surname><given-names>И. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>tatyana_ruksha@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ruksha</surname><given-names>T. G.</given-names></name><name xml:lang="ru"><surname>Рукша</surname><given-names>Т. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>tatyana_ruksha@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Voino-Yasenetsky Krasnoyarsk State Medical University</institution></aff><aff><institution xml:lang="ru">Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого, кафедра патологической физиологии</institution></aff></aff-alternatives><content-language>ru</content-language><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2024-07-15"><day>15</day><month>07</month><year>2024</year></pub-date><pub-date date-type="collection"><year>2024</year></pub-date><volume>66</volume><issue>4</issue><issue-title xml:lang="ru"/><fpage>330</fpage><lpage>340</lpage><history><date date-type="received" iso-8601-date="2025-02-27"><day>27</day><month>02</month><year>2025</year></date></history><pub-history><event event-type="received"><event-desc>Received:<date date-type="received" iso-8601-date="2025-02-27"><day>27</day><month>02</month><year>2025</year></date></event-desc></event><event event-type="pub"><event-desc>Published:<pub-date date-type="pub" publication-format="electronic" iso-8601-date="2024-07-15"><day>15</day><month>07</month><year>2024</year></pub-date></event-desc></event></pub-history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Russian Academy of Sciences</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Российская академия наук</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Russian Academy of Sciences</copyright-holder><copyright-holder xml:lang="ru">Российская академия наук</copyright-holder></permissions><self-uri xlink:href="https://vietnamjournal.ru/0041-3771/article/view/669498">https://vietnamjournal.ru/0041-3771/article/view/669498</self-uri><abstract xml:lang="en"><p>In this study, the viability and adhesive features of BRO and SK-MEL-2 cell lines were evaluated using a melanoma model. It was revealed that in BRO cells, the development of apoptosis after exposure to dacarbazine was combined with the transition of the proportion of cells to the G<sub>0</sub> phase of the cell cycle, that corresponded to previously obtained results. The absence of apoptosis in 3D spheroids and the absence of exit from the cell cycle were observed in SK-MEL-2 melanoma cells. It was also revealed that in the control spheroids (cells without exposure) of the BRO and SK-MEL-2 melanoma lines, adhesion to fibronectin was higher compared with the cells of the control monolayer, which is explained by the three-dimensional structure requiring cell communication with the extracellular matrix. In spheroids formed by SK-MEL-2 cells, dacarbazine induced a decrease in adhesion to fibronectin, which may be associated with the development of drug resistance. An increase in the expression of integrins AV and β8 in BRO and SK-MEL-2, as well as integrin β5 in SK-MEL-2, was determined in cells after exposure to dacarbazine, which may indicate the involvement of aforementioned molecules in the exit from proliferative stage of tumor cells.</p></abstract><trans-abstract xml:lang="ru"><p>В настоящей работе на модели меланомы оценивали жизнеспособность и адгезивные свойства клеток линий BRO и SK-MEL-2. Показано, что в клетках линии BRO развитие апоптоза после воздействия дакарбазином сочеталось с переходом доли клеток в фазу G<sub>0</sub> клеточного цикла, что подтверждает ранее полученные результаты. В клетках меланомы SK-MEL-2 наблюдали отсутствие апоптоза в 3D-сфероидах и отсутствие выхода из клеточного цикла. Также выявлено, что в контрольных сфероидах (клетки без воздействия) линий меланомы BRO и SK-MEL-2 адгезия к фибронектину была выше по сравнению с клетками монослоя контроля, что объясняется трехмерной структурой, требующей коммуникации клеток с внеклеточным матриксом. В сфероидах, сформированных клетками SK-MEL-2, дакарбазин индуцировал снижение адгезии к фибронектину, что может быть связано с развитием лекарственной устойчивости. После воздействия дакарбазином повышаются уровни экспрессии интегринов αV и β8 в клетках BRO и SK-MEL-2, а также интегрина β5 в клетках SK-MEL-2, что может указывать на участие этих молекул в утрате пролиферативного статуса опухолевых клеток.</p></trans-abstract><kwd-group xml:lang="en"><kwd>melanoma</kwd><kwd>spheroids</kwd><kwd>solid tumors</kwd><kwd>dacarbazine</kwd><kwd>adhesion</kwd><kwd>apoptosis</kwd><kwd>fibronectin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>меланома</kwd><kwd>сфероиды</kwd><kwd>солидные опухоли</kwd><kwd>дакарбазин, адгезия</kwd><kwd>апоптоз</kwd><kwd>фибронектин</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Российский научный фонд</institution></institution-wrap><institution-wrap><institution xml:lang="en">Russian Science Foundation</institution></institution-wrap></funding-source><award-id>№ 19-15-00110, https://rscf.ru/project/19-15-00110/</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Achill T. M., Meye J., &amp; Morgan J. R. 2012. Advances in the formation, use and understanding of multi-cellular spheroids. Exp. Op. Biol. Ther. V. 12. P. 1347. https://doi.org/10.1517/14712598.2012.707181</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Aksenenko M.B., Palkina N.V., Sergeeva O.N., Sergeeva E. Yu., Kirichenko A.K., Ruksha T.G. 2019. miR-155 overexpression is followed by downregulation of its target gene, NFE2L2, and altered pattern of VEGFA expression in the liver of melanoma B16-bearing mice at the premetastatic stage. Int. J. Exp. Pathol. V. 100. P. 311. https://doi.org/10.1111/iep.12342</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Azimian-Zavareh V., Dehghani-Ghobadi Z., Ebrahimi M., Mirzazadeh K., Nazarenko I., Hossein G. 2021. Wnt5A modulates integrin expression in a receptor-dependent manner in ovarian cancer cells. Sci. Rep. V. 11. P. 5885. doi: 10.1038/s41598-021-85356-6</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Chen G., Kawazoe N., Tateishi T. 2008. Effects of ECM proteins and cationic polymers on the adhesion and proliferation of rat islet cells. The Open Biotechnol. J. V. 2: e1874070727154. https://doi.org/10.2174/1874070700802010133</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Colella G., Fazioli F., Gallo M., De Chiara A., Apice G., Ruosi C., Cimmino A., De Nigris F. 2018. Sarcoma spheroids and organoids — promising tools in the era of personalized medicine. Int. J. Mol. Sci. V. 19. P. 615. https://doi.org/10.3390/ijms19020615</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Esimbekova A.R., Palkina N.V., Zinchenko I.S., Belenyuk V.D., Savchenko A.A., Sergeeva E.Y., Ruksha T.G. 2023. Focal adhesion alterations in G0-positivemelanoma cells. Cancer Med. V. 12. P. 7294. https://doi.org/10.1002/cam4.5510</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kewitz S., Stiefel M., Kramm C.M., &amp; Staege M.S. 2014. Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin’s lymphoma cells. Leukemia research. V. 38. P. 138. https://doi.org/10.1016/j.leukres.2013.11.001</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Komina A.V., Palkina N.V., Aksenenko M.B., Lavrentev S.N., Moshev A.V., Savchenko A.A., Averchuk A.S., Rybnikov Y.A., Ruksha T.G.2019.Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status. Melanoma Res. V. 29. P. 544. https://doi.org/10.1097/CMR.0000000000000621</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lee S. Y., Koo I. S., Hwang H. J., Lee D. W. 2023. In vitro three-dimensional (3D) cell culture tools for spheroid and organoid models. SLAS Discov. V. 29. P. 5 131. https://doi.org/10.1016/j.slasd.2023.03.006</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Lin T. C., Yang C. H., Cheng L. H., Chang W. T., Lin Y. R., Cheng H.C. 2019. Fibronectin in cancer: friend or foe. Cells. V. 9. P. 27. doi: 10.3390/cells9010027.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Livak K. J., Schmittgen T. D. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. V. 25. P. 402. https://doi.org/10.1006/meth.2001.1262</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Liu Y., Sheikh M. S. 2014. Melanoma: molecular pathogenesis and therapeutic management. Mol. Cell.Pharmacol. V. 6. P. 228.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Sakalem M. E., De Sibio M. T., da Costa F. A. D. S., de Oliveira M. 2021. Historical evolution of spheroids and organoids, and possibilities of use in life sciences and medicine. Biotechnol. J. V. 16: 2000463. https://doi.org/10.1002/biot.202000463</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Srisongkram T., Weerapreeyakul N., Thumanu K. 2020. Evaluation of melanoma (SK-MEL-2) cell growth between three-dimensional (3D) and two-dimensional (2D) cell cultures with fourier transform infrared (FTIR) microspectroscopy. Int. J. Mol. Sci. V. 21: 4141. https://doi.org/10.3390/ijms21114141</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Syed A. M., Kundu S., Ram C., Kulhari U., Kumar A., Mugale M. N., Murty U.S., Sahu B. D. 2022. Aloin alleviates pathological cardiac hypertrophy via modulation of the oxidative and fibrotic response. Life Sci., V. 288: 120159. https://doi.org/10.1016/j.lfs.2021.120159</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Zanoni M., Cortesi M., Zamagni A., Arienti C., Pignatta S., Tesei A. 2020. Modeling neoplastic disease with spheroids and organoids. J. Hematol. Oncol. V. 13. P. 1. https://doi.org/10.1186/s13045-020-00931-0</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Zanoni M., Piccinini F., Arienti C., Zamagni A., Santi S., Polico R., Bevilacqua A., Tesei A. 2016. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci. Rep. V. 6: 19103. https://doi.org/10.1038/srep19103</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Zhou J., Yi Q., Tang L. 2019. The roles of nuclear focal adhesion kinase (FAK) on cancer: a focused review. J. Exp. Clin. Cancer Res. V. 38. P. 250. https://doi: 10.1186/s13046-019-1265-1</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Wu C., Weis S. M., Cheresh D. A. 2023. Upregulation of fibronectin and its integrin receptors – an adaptation to isolation stress that facilitates tumor initiation. J. Cell Sci. V. 136: 261483. https://doi.org/10.1242/jcs.261483</mixed-citation></ref></ref-list></back></article>
